The new crown oral antiviral drug Paxlovid encountered a "half-day tour" on the shelves.
According to The Paper , on the afternoon of December 13, a certain medicine network APP pre-selled the new crown oral antiviral drug Paxlovid (Nematevir/ritonavir tablets), priced at 2,980 yuan/box. However, at around 17:30, the relevant products could not be searched in the APP, and the mobile web version showed "No quotation yet".
Regarding whether to pre-sell the new crown oral antiviral drug Paxlovid, a person from the drug network responded to the reporter: "It is not the online sale of Paxlovid drugs for Pfizer , but in accordance with the "Notice on Implementing Internet Medical Services for the New Coronavirus Pneumonia" issued by the Office of the State Council's Prevention and Control Mechanism on December 12, 2022, to provide diagnosis and treatment and medication services to eligible patients through Internet hospitals."
According to the previous sales interface, the specifications of Paxlovid are 150mg/100mg*4 tablets (pink) + 2 tablets *5 boards (white), and each user is limited to purchase 3 pieces. Shanghai area shows that orders are placed before 18 o'clock and are expected to be shipped on the same day. Before
is removed from the shelves, the option "Purchase now" is set at the bottom of the purchase interface. Users need to improve the consultation information and provide the filled-in information to the doctor as the basis for consultation, and wait for the doctor to consult before purchasing. The reporter conducted a consultation at 17:07, and the doctor did not wait until the product was taken off the shelves.
According to CCTV News, on February 11 this year, the State Food and Drug Administration conducted emergency review and approval in accordance with the special drug approval procedures, and approved Paxlovid import registration with conditions.
Paxlovid is an oral small molecule novel coronavirus treatment drug used to treat adult patients with mild to moderate novel coronavirus pneumonia (COVID-19) who have progressed to severe high-risk factors, such as patients with advanced age, chronic renal disease, diabetes and other severe high-risk factors. The report pointed out that patients should strictly follow the instructions under the guidance of a doctor, and should pay close attention to the interaction information listed in the instructions during use.
Domestic new crown oral medicine Azfuding can be prescribed online
Previously, on the evening of November 18, some media reported that Azfuding tablets were on sale online in some pharmacies, but at around 11:30 the next day, the product was removed from the shelves. Before it was taken off the shelves, a pharmacy's WeChat mini program showed that Azfu tablets were priced at 350 yuan per bottle, with a specification of 1 mg.
According to Red Star News , the exclusive commercialization partner of the domestic oral drug Azfuding confirmed that Azfuding can currently issue prescriptions online in medical institutions through the Internet diagnosis and treatment platform.
According to Southern Metropolis Daily , Azfuding is the first oral small molecule antiviral drug independently developed by my country. It was previously used for the treatment of AIDS . It is a novel nucleoside reverse transcriptase and auxiliary protein Vif inhibitor, and it is also the world's first dual-target innovative anti-AIDS drug. In July 2021, Azvdine was launched as a Class 1 innovative drug to treat adult HIV-1 infected patients with high viral load .
But after the outbreak of COVID-19 , the drug was developed into an anti-COVID-19 drug. On July 25, 2022, the State Food and Drug Administration conducted emergency review and approval, and conditionally approved the registration application for the increase in indications for the treatment of new coronavirus pneumonia. As a result, the drug became the first oral direct antiviral drug developed by a Chinese company to be approved by the State Food and Drug Administration for the treatment of COVID-19.
China Youth Daily (ID: zqbcyol compiled by: Chen Yinshan) Comprehensive: The Paper (Yang Yang Wu Yuxin), Southern Metropolis Daily, Red Star News
Source: China Youth Daily
